$1.33
4.68% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US29664W1053
Symbol
ESPR
Sector
Industry

Esperion Therapeutics, Inc. Stock price

$1.39
-0.19 12.03% 1M
-0.43 23.63% 6M
-0.81 36.82% YTD
-1.49 51.74% 1Y
-3.86 73.52% 3Y
-31.58 95.78% 5Y
-98.40 98.61% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.02 1.42%
ISIN
US29664W1053
Symbol
ESPR
Sector
Industry

Key metrics

Market capitalization $275.01m
Enterprise Value $721.46m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.17
P/S ratio (TTM) P/S ratio 0.83
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 185.66%
Revenue (TTM) Revenue $332.31m
EBIT (operating result TTM) EBIT $54.40m
Free Cash Flow (TTM) Free Cash Flow $-23.97m
Cash position $144.76m
EPS (TTM) EPS $-0.27
P/E forward 37.07
P/S forward 0.80
EV/Sales forward 2.10
Short interest 14.65%
Show more

Is Esperion Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Esperion Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Esperion Therapeutics, Inc. forecast:

6x Buy
75%
1x Hold
13%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Esperion Therapeutics, Inc. forecast:

Buy
75%
Hold
13%
Sell
13%

Financial data from Esperion Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
332 332
186% 186%
100%
- Direct Costs 69 69
58% 58%
21%
264 264
262% 262%
79%
- Selling and Administrative Expenses 163 163
26% 26%
49%
- Research and Development Expense 46 46
46% 46%
14%
54 54
138% 138%
16%
- Depreciation and Amortization 0.06 0.06
63% 63%
0%
EBIT (Operating Income) EBIT 54 54
138% 138%
16%
Net Profit -52 -52
75% 75%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Esperion Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Esperion Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E.
Neutral
Seeking Alpha
about one month ago
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Eric Warren - Chief Commercial Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Thomas ...
Neutral
GlobeNewsWire
about one month ago
– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million –
More Esperion Therapeutics, Inc. News

Company Profile

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Head office United States
CEO Sheldon Koenig
Employees 304
Founded 1998
Website www.esperion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today